Read more Canadian semaglutide sales hit $3.5 billion in 2025 IQVIA data shows the size of the market that generics are about to disrupt
This infographic provides a structured, high-yield overview aligned with clinical and academic frameworks, covering: Core pharmacology and mechanism of action Key pharmacological effects on glucose homeostasis and appetite regulation Evidence-based therapeutic indications (Type 2 Diabetes & Obesity) Safety profile including side effects, toxicity risks, and contraindications Pharmacokinetics: metabolism, half-life, and excretion pathways Drug-drug interaction considerations for clinical optimization Overview of globally recognized brands such as semaglutide, liraglutide, dulaglutide, and tirzepatide formulations From enhancing insulin secretion to delaying gastric emptying, GLP-1 analogs are redefining patient-centric outcomes with a strong efficacy-safety balance
Review your plans drug formulary or contact Humana to confirm coverage for your specific weight loss medication
1 On June 22 nd , Novo Nordisk will also host an R&D investor event on our metabolic and cardiovascular health portfolio to cover the science and abstracts presented at the congress
Forschner A, Eichner F, Amaral T, et al
